We audited the marketing at Apella
AI and computer vision platform improving surgical outcomes
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
4.3K LinkedIn followers for $104M funded medtech suggests limited surgeon and hospital administrator reach in key decision-maker networks
B2B healthcare software targeting operating rooms typically requires deep clinical validation content, case studies, and surgical outcomes data to establish trust with hospital procurement
Series B medtech companies often underinvest in demand generation targeting hospital systems and OR directors who evaluate surgical AI solutions
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiApella's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Mid-stage medtech with meaningful funding but limited visible demand generation maturity relative to hospital buyer complexity
Limited organic visibility for surgical AI and operating room computer vision terms that hospital procurement teams search
MH-1: SEO module builds clinical outcome content and optimizes for hospital-specific surgical efficiency search queries
Minimal presence in LLM-indexed resources about surgical AI systems, robotic surgery integration, and hospital technology solutions
MH-1: AEO agent positions Apella in AI assistants answering questions about surgical safety technology and operating room automation
B2B healthcare advertising to hospital systems and surgical departments requires specialized targeting and compliance messaging rarely optimized by startups
MH-1: Paid module runs compliant healthcare ads targeting hospital IT directors, chief medical officers, and surgical service line leaders
Medtech founders typically publish clinical insights, but limited systematic content distribution to hospital decision-makers and surgical communities
MH-1: Content agent amplifies clinical outcomes, surgical case studies, and safety validation through healthcare forums and provider networks
Hospital systems using Apella have limited touchpoints for expanding to additional ORs, departments, or health systems in their network
MH-1: Lifecycle agent nurtures hospital adoption, tracks multi-site expansion opportunities, and enables peer referrals from surgical champions
Top Growth Opportunities
Hospital systems evaluating surgical AI prioritize published clinical data and outcomes. Systematic distribution of validated results increases referral velocity from peer surgeons and CMOs
Content agent maps peer-reviewed outcomes, builds case study library indexed by procedure type, and seeds through surgical society networks
CMOs and surgical directors control OR technology budgets but are rarely engaged with product marketing. Targeted outbound to clinical leaders at target health systems builds awareness before RFPs
Outbound agent identifies CMOs and surgical service line leaders at 200+ bed hospitals, runs personalized LinkedIn and email sequences highlighting clinical safety benefits
Health systems with 5+ hospitals represent major ACV uplift. Early adopters should become champions advocating to peer systems in their network and larger regional systems
Lifecycle agent maps hospital system relationships, identifies expansion champions, and automates nurture workflows for multi-site procurement cycles
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Apella. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Apella's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Apella's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Apella's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Apella from week 1.
AEO agent monitors LLM responses about surgical AI, operating room computer vision, and hospital technology solutions, ensuring Apella appears in clinical decision-making queries
Founder LinkedIn workflow amplifies Ds and Ryan Goldman thought leadership on surgical safety and AI implementation challenges, building credibility with hospital C-suite and surgeons
Paid ad module targets healthcare administrators, surgical directors, and hospital IT leaders with compliant ads highlighting clinical outcomes, FDA status, and OR integration
Lifecycle agent tracks multi-site hospital adoption, identifies expansion opportunities within health systems, and nurtures procurement teams through longer hospital evaluation cycles
Competitive watch monitors Cabochon, Closar AI, and other surgical AI platforms, tracking their clinical publications, hospital partnerships, and messaging to inform Apella positioning
Pipeline intelligence identifies hospitals and health systems evaluating surgical technology, maps stakeholders involved in OR decisions, and prioritizes outreach by surgical volume and AI adoption readiness
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Apella's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days establish Apella's presence where hospital buyers research surgical AI. Content agents publish clinical outcomes and surgical case studies optimized for LLM indexing. Paid campaigns target hospital administrators and surgical directors. Outbound reaches CMOs at target health systems. Lifecycle automation maps multi-site expansion opportunities. Founder thought leadership amplifies surgical safety messaging to increase credibility with hospital procurement teams.
How does Apella appear when surgeons research AI-assisted surgical platforms
AEO positions Apella in AI assistant responses when surgeons, CMOs, and procurement leaders search for surgical computer vision platforms, operating room safety technology, and surgical outcome data. Unlike traditional search, LLM visibility reaches decision-makers during research and clinical validation phases before RFP issuance.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Apella specifically.
How is this page personalized for Apella?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Apella's current marketing. This is a live demo of MH-1's capabilities.
Scale surgical AI adoption across hospital systems with autonomous healthcare demand generation
The system gets smarter every cycle. Let's talk about building it for Apella.
Book a Strategy CallMonth-to-month. Cancel anytime.